Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2423studies indexed1086with human data145registered trials2091carry a numeric findingLibrarian added 0 studies today

Showing 7 studiesSortNewest indexed ▾

grade

Sutureless, ultra-swollen hydrogel scleral buckle for microinvasive treatment of rhegmatogenous retinal detachment.

Navepegritide · Colloids and surfaces. B, Biointerfaces · 2026 · Animal study · Preclinical

This hydrogel offers a promising alternative to traditional scleral buckling for retinal detachment, but human trials are needed to confirm its clinical applicability.

Hydrogel swells to 830% of its original volume.

summary

Full text read

Source →

grade

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.

Navepegritide · Nature medicine · 2016Top journal

Not reported in abstract.

summary

Title only

Source →

grade

Ultra-fast deep-learned CNS tumour classification during surgery.

Navepegritide · Nature · 2023Top journal

Not reported in abstract.

summary

Title only

Source →

grade

Adjunctive Middle Meningeal Artery Embolization for Subdural Hematoma.

Navepegritide · The New England journal of medicine · 2024Top journal

Not reported in abstract.

summary

Title only

Source →

grade

A Scoping Review of 5-HT<sub>3</sub> Antagonist Antiemetic Medication Safety in the Management of Nausea and Vomiting of Pregnancy.

Navepegritide · Pharmacoepidemiology and drug safety · 2024 · Review

Ondansetron appears to have a low risk of harm for pregnant women experiencing nausea and vomiting, but further investigation is needed for certain congenital anomalies.

Not reported in abstract.

summary

Full text read

Source →

grade

Longitudinal analysis of viral suppression before, during, and after pregnancy among women on antiretroviral therapy in Uganda: six-year real-world experience.

Navepegritide · HIV research & clinical practice · 2026 · Observational · n=1291

Viral suppression rates vary among different ART regimens before and after pregnancy, with adherence being a key factor for optimal outcomes.

Viral suppression rates before pregnancy were 95.0% for DTG, 94.9% for EFV, 93.1% for NVP, and 79.6% for PI-based therapy.

summary

Full text read

Source →

grade

Integrating haplotype-enhanced HIV surveillance with national databases improves the resolution of transmission networks, drug resistance, and risk assessment.

Navepegritide · Emerging microbes & infections · 2023 · Observational · n=95

Integrating haplotype sequences into HIV surveillance significantly improves the resolution of transmission networks and drug resistance detection.

91.1% sequence-level network inclusion rate (1452/1594 haplotypes)

summary

Full text read

Source →

Showing 7 of 7